Lepu Biopharma (2157) Stock Overview

Lepu Biopharma Co., Ltd., a biopharmaceutical company, focuses on developing oncology therapeutics products in China. The company offers HX008, a humanized IgG4 mAb against human PD-1for the treatment of solid tumors and melanoma. It is conducting phase III clinical study of HX008 in combination therapy with irinotecan, and Phase II clinical trials of HX008 for non-small cell lung cancer, triple-negative breast cancer, and hepatocellular carcinoma. It is also developing MRG003 for nasopharyngeal cancer, and head and neck squamous cell carcinoma and is in phase II clinical study; and MRG002, which is in phase II trials for treatment of gastric cancer, gastroesophageal junction, and urothelial cancer. Further, it is developing MRG001 CD20-targeted ADC and CMG9013 CLDN18.2-targeted ADC that are in phase II trials; and MRG004A TF-targeted ADC that is in phase 1 trials. The company was incorporated in 2018 and is headquartered in Shanghai, China.